Compare DexCom, Inc. (DXCM) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Iron Mountain Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Iron Mountain Inc trades at $114.8 (market cap $34.46B). The key difference: DexCom, Inc. and Iron Mountain Inc are close in size by market cap, and Iron Mountain Inc pays a 2.99% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Iron Mountain Inc for 80 Days on average.
| DXCM | IRM | |
|---|---|---|
Market Cap | $31.86B | $34.46B |
Volume | 3,607,070 | 1,379,608 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $133.06 |
52-Week Low | $54.84 | $78.86 |
Typical Hold Time | 62 Days | 80 Days |
Enterprise Value | $31.32B | $53.87B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Iron Mountain (IRM) trades at $114.51, down 1.05% on the day, with a bearish technical signal and elevated valuation metrics like a P/E of 82.09. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.60 surpassing the $0.543 forecast. The company is expanding its data center pipeline and digital solutions, targeting 300MW capacity, while revenue grew to $6.90 billion in 2025. However, net income margin has declined to 2.09%, and debt-to-asset ratio rose to 79.04% in 2025, indicating financial leverage concerns.
The outlook is mixed: strong analyst consensus with a $142.75 price target and 66.7% buy ratings support upside potential, but high debt, margin pressure, and bearish technicals pose risks. Growth in data centers and digital services offers opportunity, yet investors must weigh leverage and profitability trends against expansion prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
